Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1963 1
1964 2
1965 1
1966 1
1967 1
1968 1
1969 2
1970 1
1971 2
1972 3
1973 3
1974 1
1975 6
1976 2
1977 2
1978 1
1979 2
1980 4
1981 1
1982 1
1983 6
1984 8
1985 10
1986 12
1987 10
1988 5
1989 17
1990 13
1991 16
1992 19
1993 16
1994 20
1995 14
1996 22
1997 21
1998 32
1999 38
2000 34
2001 36
2002 32
2003 25
2004 22
2005 21
2006 24
2007 36
2008 45
2009 46
2010 58
2011 81
2012 86
2013 92
2014 73
2015 87
2016 68
2017 58
2018 65
2019 82
2020 100
2021 104
2022 82
2023 70
2024 68

Text availability

Article attribute

Article type

Publication date

Search Results

1,606 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression.
Devalaraja S, To TKJ, Folkert IW, Natesan R, Alam MZ, Li M, Tada Y, Budagyan K, Dang MT, Zhai L, Lobel GP, Ciotti GE, Eisinger-Mathason TSK, Asangani IA, Weber K, Simon MC, Haldar M. Devalaraja S, et al. Among authors: tada y. Cell. 2020 Mar 19;180(6):1098-1114.e16. doi: 10.1016/j.cell.2020.02.042. Epub 2020 Mar 12. Cell. 2020. PMID: 32169218 Free PMC article.
Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus.
Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng RX, Otomo N, Laurynenka V, Kwon YC, Sheng Y, Sugano N, Hwang MY, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung WT, Huang H, Takahashi D, Lee SS, Wang M, Karino K, Shim SC, Zheng X, Miyamura T, Kang YM, Ye D, Nakamura J, Suh CH, Tang Y, Motomura G, Park YB, Ding H, Kuroda T, Choe JY, Li C, Niiro H, Park Y, Shen C, Miyamoto T, Ahn GY, Fei W, Takeuchi T, Shin JM, Li K, Kawaguchi Y, Lee YK, Wang Y, Amano K, Park DJ, Yang W, Tada Y, Yamaji K, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y; Japanese Research Committee on Idiopathic Osteonecrosis of the Femoral Head; Kottyan LC, Weirauch MT, Parameswaran S, Eswar S, Salim H, Chen X, Yamamoto K, Harley JB, Ohmura K, Kim TH, Yang S, Yamamoto T, Kim BJ, Shen N, Ikegawa S, Lee HS, Zhang X, Terao C, Cui Y, Bae SC. Yin X, et al. Among authors: tada y. Ann Rheum Dis. 2021 May;80(5):632-640. doi: 10.1136/annrheumdis-2020-219209. Epub 2020 Dec 3. Ann Rheum Dis. 2021. PMID: 33272962 Free PMC article.
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, Hirai H, Yamada S, Kawakita D, Miura K, Kamata SE, Nagao T. Takahashi H, et al. Among authors: tada y. J Clin Oncol. 2019 Jan 10;37(2):125-134. doi: 10.1200/JCO.18.00545. Epub 2018 Nov 19. J Clin Oncol. 2019. PMID: 30452336 Clinical Trial.
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, Matsuki T, Miura K, Kawakita D, Hirai H, Hoshino E, Kamata S, Saotome T. Fushimi C, et al. Among authors: tada y. Ann Oncol. 2018 Apr 1;29(4):979-984. doi: 10.1093/annonc/mdx771. Ann Oncol. 2018. PMID: 29211833 Free PMC article. Clinical Trial.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Among authors: tada y. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S, Tada Y, Hippeli L, Banerjee S, Morita A, Ohtsuki M. Imafuku S, et al. Among authors: tada y. J Dermatol. 2023 May;50(5):588-595. doi: 10.1111/1346-8138.16740. Epub 2023 Mar 7. J Dermatol. 2023. PMID: 36882942 Clinical Trial.
1,606 results